Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Tris Pharma, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01939366CT.gov Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves | — | Completed | — | — | — |
NCT01347671CT.gov Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetic Neuropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cebranopadol (this asset) | Tris Pharma, Inc. | P2 | B · 62 |
| Duloxetine | Aga Khan University | P4 | A |
| Gabapentin | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Mirogabalin | Bangladesh Medical University | P4 | BBB |
| Capsaicin | Corporacion Parc Tauli | P4 | BBB |
| Lidocaine | Corporacion Parc Tauli | P4 | BBB |
| Pregabalin | Shandong Suncadia Medicine Co., Ltd. | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Irmandade da Santa Casa de Misericordia de Sao Paulo | P3 | BB |
| Tapentadol | Janssen Pharmaceutical K.K. | P3 | BB |
+42 more in the Diabetic Neuropathy cohort
Other indications for Cebranopadol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P3 | B · 60 |
| Osteoarthritis, Knee | — | P2 | B · 57 |
| Diabetic Polyneuropathy | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cebranopadol in Diabetic Neuropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cebranopadol-diabetic-neuropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →